A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT02009449. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors
Study identification
- NCT ID
- NCT02009449
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Eli Lilly and Company
- Industry
- Enrollment
- 353 participants
Conditions and interventions
Conditions
Interventions
- Capecitabine Drug
- FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil) Drug
- Gemcitabine/carboplatin Drug
- Paclitaxel Drug
- Paclitaxel or Docetaxel and Carboplatin or Cisplatin Drug
- Pazopanib Drug
- Pegilodecakin Drug
- Pembrolizumab Drug
- gemcitabine/nab-paclitaxel Drug
- nivolumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 14, 2013
- Primary completion
- Feb 18, 2019
- Completion
- Jul 21, 2023
- Last update posted
- Nov 14, 2024
2013 – 2023
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Medical Hematology & Oncology | Los Angeles | California | 90024 | — |
| UCSF | San Francisco | California | — | — |
| Sarah Cannon Research Institute at HealthONE | Denver | Colorado | 80218 | — |
| Florida Cancer Specialists & Research Institute | Sarasota | Florida | 34232 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Stephenson Cancer Center at Oklahoma University TSET Phase 1 Program | Oklahoma City | Oklahoma | 73104 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| The University of Texas M.D. Anderson Cancer Center | Houston | Texas | 77030 | — |
| South Texas Accelerated Research Therapeutics | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02009449, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 14, 2024 · Synced Apr 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02009449 live on ClinicalTrials.gov.